Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Small Cell Lung Carcinoma
- Large Cell Neuroendocrine Carcinoma of the Lung
- Neuroendocrine Prostate Cancer
- Gastroenteropancreatic Neuroendocrine Carcinoma
- Non-prostate Extrapulmonary Neuroendocrine Carcinoma
- Cervical Neuroendocrine Carcinoma
- Thymic Neuroendocrine Carcinoma
- Genitourinary Neuroendocrine Carcinoma
- Unknown Primary Neuroendocrine Carcinomas
- Merkel Cell Carcinoma
- Medullary Thyroid Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novartis Pharmaceuticals
- Last updated on ClinicalTrials.gov
- September 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Iowa · 1
- University Of Iowa · Iowa City, IA
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Michigan · 1
- Corewell Health William Beaum Hosp · Royal Oak, MI
Washington · 1
- Fred Hutchinson Cancer Research Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.